GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Cyclically Adjusted Price-to-FCF

Galapagos NV (Galapagos NV) Cyclically Adjusted Price-to-FCF : 10.82 (As of Jun. 02, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Cyclically Adjusted Price-to-FCF?

As of today (2024-06-02), Galapagos NV's current share price is $27.80. Galapagos NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $2.57. Galapagos NV's Cyclically Adjusted Price-to-FCF for today is 10.82.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

GLPG' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 7.73   Med: 11.31   Max: 21.6
Current: 10.89

During the past years, Galapagos NV's highest Cyclically Adjusted Price-to-FCF was 21.60. The lowest was 7.73. And the median was 11.31.

GLPG's Cyclically Adjusted Price-to-FCF is ranked better than
93.33% of 105 companies
in the Biotechnology industry
Industry Median: 50.31 vs GLPG: 10.89

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Galapagos NV's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $-2.124. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $2.57 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted Price-to-FCF Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 11.78 9.96 11.20 14.22

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.40 12.25 11.70 14.22 12.51

Competitive Comparison of Galapagos NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted Price-to-FCF falls into.



Galapagos NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Galapagos NV's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=27.80/2.57
=10.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Galapagos NV's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.124/130.5518*130.5518
=-2.124

Current CPI (Mar. 2024) = 130.5518.

Galapagos NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 99.482 0.000
201409 0.000 99.195 0.000
201412 0.000 99.086 0.000
201503 -1.185 99.423 -1.556
201506 -1.026 100.107 -1.338
201509 -0.868 100.245 -1.130
201512 -0.737 100.572 -0.957
201603 6.131 101.653 7.874
201606 -0.544 102.267 -0.694
201609 -0.632 102.118 -0.808
201612 0.781 102.614 0.994
201703 -0.552 103.972 -0.693
201706 -0.669 103.902 -0.841
201709 -0.848 104.170 -1.063
201712 -1.517 104.804 -1.890
201803 -0.998 105.419 -1.236
201806 -1.209 106.063 -1.488
201809 -0.126 106.618 -0.154
201812 -1.164 107.252 -1.417
201903 -1.550 107.876 -1.876
201906 -1.549 107.896 -1.874
201909 63.541 107.470 77.188
201912 -2.371 108.065 -2.864
202003 -1.328 108.550 -1.597
202006 -2.648 108.540 -3.185
202009 -3.612 108.441 -4.348
202012 -1.545 108.511 -1.859
202103 -2.314 109.522 -2.758
202106 -1.715 110.305 -2.030
202109 -2.737 111.543 -3.203
202112 -3.215 114.705 -3.659
202203 -1.185 118.620 -1.304
202206 -2.404 120.948 -2.595
202209 -1.936 124.120 -2.036
202212 -3.281 126.578 -3.384
202303 -1.601 126.528 -1.652
202306 -2.142 125.973 -2.220
202309 -1.961 127.083 -2.015
202312 -1.247 128.292 -1.269
202403 -2.124 130.552 -2.124

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (NAS:GLPG) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Galapagos NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.